Adverse events of targeted therapies.
There is currently an explosion in the number of so-called targeted therapies. As new indications for these agents multiply, there is also an increase of new and less new side-effects. Given this rapidly evolving field, any literature on that topic is rapidly obsolete and needs re-evaluation. Targeted therapies are associated with a wide spectrum of adverse events, which cannot always be easily separated from the complications linked to cancer, its therapy, and comorbidities. A high awareness of these events might improve the patient's quality of life and contribute to the recognition of new syndromes.